Supplementary Figure from BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma

Mehnert, Janice M.; Mitchell, Tara C.; Huang, Alexander C.; Aleman, Tomas S.; Kim, Benjamin J.; Schuchter, Lynn M.; Linette, Gerald P.; Karakousis, Giorgos C.; Mitnick, Sheryl; Giles, Lydia; Carberry, Mary; Frey, Noelle; Kossenkov, Andrew; Groisberg, Roman; Hernandez-Aya, Leonel F.; Ansstas, George; Silk, Ann W.; Chandra, Sunandana; Sosman, Jeffrey A.; Gimotty, Phyllis A.; Mick, Rosemarie; Amaravadi, Ravi K.

doi:10.1158/1078-0432.22487178.v1

Supplementary Figure from BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma

journal contribution

posted on 2023-03-31, 23:46 authored by Janice M. Mehnert, Tara C. Mitchell, Alexander C. Huang, Tomas S. Aleman, Benjamin J. Kim, Lynn M. Schuchter, Gerald P. Linette, Giorgos C. Karakousis, Sheryl Mitnick, Lydia Giles, Mary Carberry, Noelle Frey, Andrew Kossenkov, Roman Groisberg, Leonel F. Hernandez-Aya, George Ansstas, Ann W. Silk, Sunandana Chandra, Jeffrey A. Sosman, Phyllis A. Gimotty, Rosemarie Mick, Ravi K. Amaravadi

Supplementary Figure from BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

History

ARTICLE ABSTRACT

Autophagy is a resistance mechanism to BRAF/MEK inhibition in BRAFV600-mutant melanoma. Here we used hydroxychloroquine (HCQ) to inhibit autophagy in combination with dabrafenib 150 mg twice daily and trametinib 2 mg every day (D+T). We conducted a phase I/II clinical trial in four centers of HCQ + D+T in patients with advanced BRAFV600-mutant melanoma. The primary objectives were the recommended phase II dose (RP2D) and the one-year progression-free survival (PFS) rate of >53%. Thirty-four patients were evaluable for one-year PFS rate. Patient demographics were as follows: elevated lactate dehydrogenase: 47%; stage IV M1c/M1d: 52%; prior immunotherapy: 50%. In phase I, there was no dose-limiting toxicity. HCQ 600 mg orally twice daily with D+T was the RP2D. The one-year PFS rate was 48.2% [95% confidence interval (CI), 31.0%–65.5%], median PFS was 11.2 months (95% CI, 5.4–16.9 months), and response rate (RR) was 85% (95% CI, 64%–95%). The complete RR was 41% and median overall survival (OS) was 26.5 months. In a patient with elevated LDH (n = 16), the RR was 88% and median PFS and OS were 7.3 and 22 months, respectively. HCQ + D+T was well tolerated and produced a high RR but did not meet criteria for success for the one-year PFS rate. There was a high proportion of patients with pretreated and elevated LDH, an increasingly common demographic in patients receiving targeted therapy. In this difficult-to-treat population, the RR and PFS were encouraging. A randomized trial of D+T + HCQ or placebo in patients with BRAFV600-mutant melanoma with elevated LDH and previous immunotherapy is being conducted.